Akorn, Inc. Names Russell A. Gall, Vice-President and General Manager, Decatur Operations.

BUFFALO GROVE, Ill. -- Akorn, Inc. (AMEX:AKN) today announced the appointment of Russell A. Gall as Vice President and General Manager, Decatur Operations. Mr. Gall brings twenty-five years experience in pharmaceutical operations management to his new role at Akorn.

Since 2004, Mr. Gall has served as Vice-President, Operations at Hospira, Inc., formerly a division of Abbott Laboratories, with responsibility for their Rocky Mount, NC, Buffalo, NY and Clayton, NC facilities, which employ over 2500 people. From 1999 to 2004, Mr. Gall served first as Director of Operations and later as Divisional Vice President for Abbott Laboratories, Rocky Mount Operations. From 1994 to 1999 he was Plant Manager of Abbott's McPherson, KS facility, previously owned by Sterling-Winthrop and Sanofi Inc. From 1990 to 1993 Mr. Gall served as Senior Director of Operations at Survival Technology Inc. (now Meridian Medical Inc.).

Mr. Gall holds a B.S. in Microbiology/Public Health and a B.S in Package Engineering, both from Michigan State University.

Arthur S. Przybyl, president and chief executive officer, stated, "We are excited to have Russ join our executive leadership team. He brings substantial operations management experience in specialty pharmaceuticals to Akorn and we are confident that he will be a great asset. "

About Akorn, Inc.

Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals. Additional information is available at the Company's website at www.akorn.com.

Any statements made by Akorn, Inc. ("we," "us," "our," "Akorn" or the "Company") in this press release that are forward looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that important factors may affect the Company's actual results and could cause such results to differ materially from forward-looking statements made by or on behalf of the Company. Such factors include, but are not limited to, risks and uncertainties relating to (i) the ability to generate cash from operations sufficient to meet the Company's working capital requirements, (ii) the necessity of complying with various regulatory procedures in the manufacture of drug products, (iii) the Company's ability to acquire, develop, finance, test, produce and market new products, including the availability of materials to produce products, (iv) the resolution of the FDA compliance issues at the Company's Decatur, Illinois manufacturing facility and the outcome of other legal proceedings involving the Company, (v) patent protection for the Company's intellectual property or trade secrets, and (vi) other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission including, but not limited to, those risks referenced under the caption "Factors That May Affect Future Results" in Item 1 of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2004.